Trial Profile
A 12-WEEK STUDY EVALUATING THE EFFECTS OF NIACIN ON VASCULAR HEALTH ASSESSED BY Fluorodeoxyglucose-PET/CT AND CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND MICROPARTICLES
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Niacin (Primary)
- Indications Arteriosclerosis
- Focus Pharmacodynamics
- Acronyms AVANT
- 18 Dec 2013 New trial record